Sign in

Trial result ·

Long-term post-trial extension of osilodrostat therapy in selected Canadian patients with Cushing disease from the LINC 3 and LINC 4 programs.

Written based on 1 research study on PubMed, searched on 13 Nov 2026.

What was studied

This study looked at people in Canada with Cushing disease. They had taken osilodrostat in the LINC 3 or LINC 4 trials. After those trials, they went on with the drug in a follow-up study. The team looked back at the records of 11 people. Of these, 7 went on to a later Canadian study. The other 4 stopped the drug earlier, for set reasons. The team tracked urine cortisol, drug dose, tumor size and side effects.

What they found

All 11 people got their urine cortisol into range. This took a median of 5 weeks, from 2 to 12 weeks. Median urine cortisol started at 2.65 times the upper normal limit. By week 14, it had fallen to 0.56 times that limit. 7 people stayed on the drug long term. Of these, 6 were still in range at the last visit. By then they had taken it for a median of 98 months. Doses varied a lot. Some people needed lower doses as time went on. Low cortisol events were common. These were handled by pausing or cutting the dose, plus brief steroid use. In 2 people, the pituitary tumor grew enough to matter. Both stopped the drug and had surgery.

What it means for patients

The authors say osilodrostat was linked to fast cortisol control. In many people, this lasted for up to 10 years. They say long-term use, with a dose set for each person, seems doable. Doctors still need to keep changing the dose as needed. They also need to watch for low cortisol and for tumor growth.

Why it is not certain yet

Only 11 people were in this study. The people were selected, so they may not reflect all patients. The team looked back at past records rather than planning ahead. The cortisol numbers were only described, with no tests to check them. Also, 4 people stopped the drug early.

Source

Long-term post-trial extension of osilodrostat therapy in selected Canadian patients with Cushing disease from the LINC 3 and LINC 4 programs.

PubMed · PMID 42935875

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Cushing's syndrome publications
Long-term post-trial extension of osilodrostat therapy in selected Canadian patients with Cushing disease from the LINC 3 and LINC 4 programs. · Cushing's syndrome news explained – Frontlight Research